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Abstract
Background & Aims—Radiofrequency ablation (RFA) can eradicate dysplasia and intestinal
metaplasia in patients with dysplastic Barrett’s esophagus (BE), and reduce rates of esophageal
adenocarcinoma. We assessed long-term rates of eradication, durability of neosquamous
epithelium, disease progression, and safety of RFA in patients with dysplastic BE.
Methods—We performed a randomized trial of 127 subjects with dysplastic BE; after cross-over
subjects were included 119 received RFA. Subjects were followed for a mean time of 3.05 years;
the study was extended to 5 years for patients with eradication of intestinal metaplasia at 2 years.
Outcomes included eradication of dysplasia or intestinal metaplasia after 2 and 3 years, durability
of response, disease progression, and adverse events.
Results—After 2 years, 101/106 patients had complete eradication of all dysplasia (95%) and
99/106 had eradication of intestinal metaplasia (93%). After 2 years, among subjects with initial
low-grade dysplasia, all dysplasia was eradicated in 51/52 (98%) and intestinal metaplasia was
eradicated in 51/52 (98%); among subjects with initial high-grade dysplasia, all dysplasia was
eradicated in 50/54 (93%) and intestinal metaplasia was eradicated in 48/54 (89%). After 3 years,
dysplasia was eradicated in 55/56 of subjects (98%) and intestinal metaplasia was eradicated in
51/56 (91%). Kaplan-Meier analysis showed that dysplasia remained eradicated in >85% of
patients and intestinal metaplasia in >75%, without maintenance RFA. Serious adverse events
occurred in 4/119 subjects (3.4%); the rate of stricture was 7.6%. The rate of esophageal
adenocarcinoma was 1/181 pt-yrs (0.55%/pt-yr); there was no cancer-related morbidity or
mortality. The annual rate of any neoplastic progression was 1/73 pt-yrs (1.37%/pt-yr).
Conclusion—In subjects with dysplastic BE, RFA therapy has an acceptable safety profile, is
durable, and is associated with a low rate of disease progression, for up to 3 years.
Keywords
esophagus; cancer; prevention; endoscopic therapy
Several treatment options are available for the care of subjects with dysplastic Barrett’s
esophagus (BE), including intensive endoscopic surveillance, esophagectomy, endoscopic
mucosal resection (EMR), and endoscopic ablative therapy.1 The choice between these
modalities is made with consideration of the severity of dysplasia (low-grade dysplasia
(LGD) vs. high-grade dysplasia (HGD)), the patient co-morbidities, the available physician
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expertise in providing the treatments, and other factors.2, 3 A paucity of literature guides the
choice in selection of the most effective therapy for dysplastic BE.
Recently, several groups have reported their experience with endoscopic ablative therapy
using radiofrequency ablation (RFA) for dysplastic BE.4–7 These reports generally
demonstrate high rates of complete eradication of dysplasia (CE-D) and intestinal metaplasia
(CE-IM) and reduction in neoplastic progression, with few serious adverse events. Despite
these promising outcomes, the longer term durability of these mucosal changes is less well-
understood, and most of these studies are either cross-sectional or have relatively short
periods of follow-up.
The AIM Dysplasia trial is a multi-center, randomized, sham-controlled trial comparing
RFA plus endoscopic surveillance to endoscopic surveillance alone for the treatment of
dysplastic BE. The 1 year outcomes of this trial demonstrated CE-D in 85.7% by intention-
to-treat analysis (92.3% per protocol), CE-IM in 77.4% of subjects by intention-to-treat
analysis (83.3% per protocol), and decreased rates of disease progression and cancer
incidence in the treated groups.7 Subjects initially randomized to the sham group were
offered cross-over to active treatment (RFA) after 1 year. All subjects were followed for 2
years after initial RFA. Subjects who achieved CE-IM at 2-year follow-up (or who were
salvaged with a single additional RFA treatment after failing to achieve CE-IM at 2 years)
were eligible to enter a trial extension, an additional 3 year period of enrollment and
endoscopic observation with biopsy to assess the durability of the neosquamous epithelium
after RFA and longer term outcomes such as neoplastic progression. The current report
describes the two- and three-year outcomes of the trial.
Methods
Study Design
Participants were recruited at 19 U.S. sites. Subjects were aged 18–80, and had
endoscopically evident, non-nodular, dysplastic BE ≤8 cm in length confirmed by a central
pathology laboratory. For subjects with HGD, we additionally required an endoscopic
ultrasound negative for lymphadenopathy or esophageal wall abnormalities within 12
months of enrollment. Previous EMR was permissible ≥8 weeks prior to entry, provided that
subsequent endoscopy demonstrated non-nodular dysplasia. Exclusion criteria included
pregnancy, active esophagitis or stricture, history of esophageal malignancy, varices,
uncontrolled coagulopathy, or life expectancy of <2 years, as judged by the investigator.
Subjects’ cancer risk and conventional treatment options (including esophagectomy in
subjects with HGD) were reviewed with all participants, and subjects provided written
informed consent. Further details of patient selection have been published previously.7
Subjects were randomly assigned in a 2:1 ratio to receive either RFA or a sham endoscopic
procedure (SHAM). Randomization was stratified by grade of dysplasia (LGD vs. HGD) at
study entry and endoscopic length of BE (<4 cm vs. 4–8 cm). All underwent upper
endoscopy, esophageal intubation with a study catheter, measurement of the esophageal
inner diameter,8 and in-room assignment of treatment group (RFA vs. SHAM) using a
computer-generated block randomization sequence. In subjects assigned to RFA, the entire
BE segment was ablated circumferentially. In SHAM, the study catheter was removed and
procedure terminated.
RFA subjects could receive up to four RFA sessions in the first year, performed at 0, 2, 4,
and 9 months and based on interval biopsy results, and one RFA session in the second year
(15 months). The month 15 treatment was mandatory for patients who failed to achieve CE-
IM at 1 year, but could also be optionally delivered based on endoscopist preference (for
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instance, mild irregularity of the Z line), and was not driven by histologic biopsy results
from previous sessions.
The treatment protocol has been described previously.7 An initial treatment was performed
with a HALO360 device, the circumferential balloon catheter, with settings of 12 J/cm2 and
300 Watts (BÂRRX Medical, Inc., Sunnyvale, CA, USA). Any necessary follow-up
treatments of residual BE were performed with a HALO90 device, an electrode array
mounted on an articulated platform, affixed to the tip of the endoscope. Subjects underwent
endoscopy with biopsy at 6 and 12 months (LGD arm), or 3, 6, 9 and 12 months (HGD
arm). Endoscopic biopsies were performed with maximum-capacity or jumbo forceps in 4
quadrants every 1 cm throughout the original length of BE, with the most distal biopsies 3–5
mm above the gastric folds, plus directed biopsies of any visible abnormalities. After
completion of the 12 month assessment, subjects in the sham arm were offered cross-over to
active (RFA) treatment. All subjects were followed for 2 years after initial RFA therapy,
with endoscopy and biopsy intervals as above, based on study entry pathology. Because
subjects initially assigned to SHAM spent 12 months without ablative therapy, the earliest
time 0 endoscopy in the SHAM group occurred after the patient had been in the study for at
least 13 months.
Subjects demonstrating CE-IM at 2 years were eligible for participation in a 3 year study
extension. The purpose of this extension was to assess the longterm durability of changes
induced by RFA, and outcomes associated with treatment. Subjects who did not achieve CE-
IM at 2 years were offered a single salvage RFA treatment at that time with repeat biopsy 2
months later. Those with CE-IM at repeat biopsy were then eligible for the study extension.
The study extension provided for three additional years of follow-up for these subjects (to a
total of 5 years), with annual surveillance endoscopies with biopsies identical in
methodology to the primary protocol. All subjects in the trial extension were maintained on
esomeprazole 40 mg twice daily.
The protocols for both the parent trial and the extension were approved by all institutions’
ethics committees, and the trial was performed in accordance with the Declaration of
Helsinki. An independent data and safety monitoring committee monitored the trial. Data
were collected by the academic sites, and the database managed by the sponsor. The
database was transferred to the authors and the independent study statistician (JAG) for
analysis. Analysis was performed by the statistician and the primary author, who vouch for
the data and the analysis. The first draft of the manuscript was written by the primary author,
who subsequently incorporated edits from the other authors.
Outcomes
The outcomes assessed included treatment success, defined as the proportion of subjects
who demonstrated CE-D and CE-IM (separately reported). Because ablative therapy might
be used as either a chronic suppressive therapy for dysplastic BE, allowing for recurrent
“touch-up” therapy of any recurrent BE, or as a single series of applications with no further
maintenance therapy after achieving CE, we calculated treatment success in two ways:
1. Proportion of subjects demonstrating CE-D and CE-IM at the 2 and 3 year biopsy
sessions, allowing interim focal touch-up RFA treatment as indicated for
histological evidence of interval recurrence. In this analysis, time 0 is considered
the first RFA treatment, and all enrolled subjects are included, and,
2. Proportion of subjects attaining, then maintaining CE-D and CE-IM, where any
recurrent dysplasia or IM, respectively, after initial CE at 1 year or later was
considered a failure of therapy for that outcome, even if the subject could again
attain CE-D or CE-IM with an additional focal RFA treatment. In this durability
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analysis, time 0 is considered the first histological analysis at 12 months or greater
demonstrating CE-D or CE-IM (ie, the start of the intervention-free period), and
only subjects attaining one or both of these endpoints (n=110 for CE-D, n=108 for
CE-IM) appear in the survival analyses.
We also assessed disease progression, defined as any patient with LGD histology at study
entry demonstrating HGD or EAC at any follow-up, or any patient with HGD histology at
study entry demonstrating EAC at any follow-up. Additionally, we assessed the rate of
serious adverse events, defined as any untoward medical event that resulted in death, was
life-threatening, required hospitalization or prolongation of ongoing hospitalization, or
resulted in persistent/significant incapacity. Stricture rate, defined as an endoscopically-
identified narrowing of the esophageal lumen, with or without accompanying dysphagia,
was calculated on a per-patient and per-procedure basis.
Histological Analysis
The histological analysis of subjects on study entry has been previously described.7
Esophageal biopsy specimens for eligible subjects having a home institution diagnosis of
dysplastic BE underwent review by the expert central pathology laboratory. If the grade of
dysplasia reading for the specimens between home institution and central laboratory were
concordant, the subject was eligible and assigned an entry grade of dysplasia (LGD or
HGD). If discordant, a second masked review was performed by the central laboratory, with
assignment by concordance.
At follow-up endoscopic biopsy sessions, tissue biopsies were fixed in formalin and sent to
the central pathology laboratory for standardized processing, and interpreted by the central
laboratory expert pathologists using standardized criteria.9 Each biopsy specimen was
assessed for tissue type and subsquamous IM, defined as IM beneath a layer of squamous
epithelium. Each biopsy containing IM was assessed for the worst histological grade. Any
biopsy containing dysplasia on first reading underwent a confirmatory masked review by a
second pathologist, and, in cases of disagreement, a third review with assignment by
concordance. The worst histological grade present was the overall histological grade for that
session.
Statistical Analysis
Power calculations have been previously described relating to the study’s primary 1-year
endpoints. Two methods were used to calculate the proportion of RFA subjects with CE-D
and CE-IM. To assess the proportion of subjects free of disease at a given time point, and
allowing interim touch-up therapy with RFA, the number of subjects with CE-D and CE-IM
was divided by the total number of RFA subjects reaching the time point. To assess the
durability of CE-D and CE-IM and considering any interim treatment after achieving
complete eradication as a failure for the outcome, survival analysis using Kaplan-Meier
estimation was performed. To compare demographic and disease-specific features of those
attaining CE-D and CE-IM to those who did not, Fisher’s exact test was used for categorical
data and Student’s t test was used for continuous data. Logistic regression was used to
control for potential confounders and assess for predictors of response to therapy. For all
outcomes, a two-sided p value <0.05 was considered statistically significant. All analyses
were performed using SAS software, version 9 (SAS Institute, Cary, NC).
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Enrollment and Characteristics of Subjects Undergoing Treatment
Of 755 subjects screened, 127 (64 LGD, 63 HGD) were randomized (84 RFA, 43 SHAM)
and 117 (78 RFA, 39 SHAM) completed 1-year follow-up, as reported previously.7 After
reaching the 1 year primary endpoint, 35 of 39 subjects from SHAM were eligible for cross-
over to RFA treatment and all elected to receive treatment. The remaining 4 of 39 developed
EAC prior to the 1 year primary outcome and were not eligible for cross-over. In all, 119
subjects underwent RFA in this trial (84 RFA at study outset plus 35 SHAM crossed over to
RFA after 1 year), representing the safety and efficacy cohort for this report (58 LGD, 61
HGD) (table 1). All available subjects (n=106) have now reached the 2 year follow-up mark
(52 LGD, 54 HGD). Thirteen of the 119 subjects have left the cohort before the year 2 time
point, for reasons including: patient/physician preference (n=5); unrelated, life-limiting, co-
morbid conditions (n=3); patient relocation/unreachable (n=3); and death from an unrelated
cause (n=2; ocular melanoma and gunshot wound). Six of the remaining 106 subjects were
ineligible for the study extension, due to lack of CE-IM at the year 2 time-point. Of the 100
subjects eligible for the study extension, to date, 56 subjects have completed year 3 follow-
up (32 LGD and 24 HGD), with the remainder not yet completing the year 3 time-point. The
mean period of follow-up from first RFA treatment in the cohort is 3.05 years (standard
deviation 1.08 years), and the median is 3.34 years (interquartile range, 2.35 years to 3.88
years). Figure 1 details the flow and accountability of all subjects through the study.
Durability of Neosquamous Epithelium
At 2-year follow-up, in the overall cohort, 101/106 (95%) of subjects had CE-D and 99/106
(93%) had CE-IM. Outcomes according to study entry grade show that CE-D and CE-IM
were achieved in 51/52 (98%) and 51/52 (98%) of LGD subjects, and 50/54 (93%) and
48/54 (89%) of HGD subjects, respectively (table 2). Focal RFA was used in 65 of 119
(55%) subjects after the 1 year primary endpoint, but only 25 of 65 treatments (38%) were
indicated based on prior biopsy results while 40 of 65 (62%) were performed at the
endoscopist’s discretion as described previously (month 15, non-histology-based endoscopy
session). Although subjects withdrew consent for continued participation for a variety of
reasons as noted above, in the most stringent analysis, if we include any subject who ever
received any RFA and left the trial before the 2 year endpoint as a failure (n=13), the
response rates were 101/119 (85%) CE-D and 99/119 (83%) CE-IM. At 3-year follow-up,
55/56 (98%) of available subjects had CE-D and 51/56 (91%) of available subjects had CE-
IM.
For subjects attaining CE-D or CE-IM at 1 year or later, an analysis of durability was
performed using Kaplan-Meier estimation as noted above. Figure 2 demonstrates the
durability of CE-D in the 110/119 subjects who attained CE-D at or after the 12 month
endpoint, considering any recurrent dysplasia as a failure even if subsequent RFA resulted in
reestablishment of CE-D. Greater than 85% of HGD patients and 90% of LGD patients
remained free of dysplasia at a mean follow-up of greater than 3 years with no additional
therapy. Figure 3 demonstrates the durability of CE-IM in the 108/119 subjects who attained
CE-IM at or after the 12 month endpoint, again considering any recurrent IM as a failure
even if subsequent RFA resulted in reestablishment of CE-IM. Greater than 75% of HGD
patients and LGD patients remained free of IM, again with follow-up of greater than 3 years,
with no additional therapy.
Among subjects who attained CE-IM, but then experienced recurrence of IM at or after the 1
year follow-up (n=14), the surface area of recurrence was minimal. In 7 of 14 subjects,
recurrent IM was detected in subjects felt to have an endoscopically “normal appearing z-
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line” (n=4) or an “irregular z-line” (n=3). In the remaining 7 subjects, 3 were noted
endoscopically to have an isolated island of BE ≤2 cm in diameter, and 4 had a tongue of
BE ≤2 cm. Within subjects with recurrence of IM, a mean of 37.2 biopsy specimens were
obtained per patient during the endoscopy session at which recurrent BE was noted. Of these
37.2 biopsies per patient, 1.4 biopsies (3.8%) per patient demonstrated IM, with the
remainder demonstrating normal tissue. In 11 of these 14 subjects, the grade of dysplasia at
the time of recurrence was at or below study entry grade. Of the 14 subjects with
histological recurrence of BE after RFA, 4 subjects (28.5%) demonstrated sub-squamous
intestinal metaplasia (SSIM) equating to a total year 2 SSIM prevalence of 4/106 (3.8%) in
the cohort, compared to the baseline prevalence of SSIM at study entry (pre-RFA) of 25.2%.
Two of the 4 subjects with SSIM had this finding only in biopsies taken from the top of the
gastric folds, and, in the other 2, one biopsy each, from 2 and 6 cm above the top of the
gastric folds, respectively, demonstrated SSIM. In 2 of the 4 subjects with SSIM, the
endoscopic appearance was normal. The remaining two subjects with SSIM were noted
endoscopically to have a 5 mm tongue of BE and an irregular Z line, respectively. With
further RFA therapy, 8 of the 14 patients with recurrent IM re-attained CE-IM, with none
requiring more than a single additional treatment to re-attain CE-IM. In 5/14 cases, the
physician or patient elected to have no further RFA treatment, and in a single case, the
treatment was ongoing at the time of this analysis.
Disease Progression
Five of 119 subjects (4.2%) who received any RFA as part of this trial have experienced
disease progression, as defined above. In an overall observation period of 363 years, this
corresponds to an annual rate of overall disease progression of 1/73 patient-years, or 1.37%
per patient per year, and an annual rate of progression to EAC of 1/181 patient-years, or
0.55% per patient per year. Stratified by baseline histology at study entry, for subjects
enrolled with LGD, the annual rate of overall disease progression was 1/49 patient-years, or
2.04% per patient per year, and the annual rate of progression to EAC was 1/197 patient-
years, or 0.51% per patient per year. Among subjects enrolled with HGD, the annual rate of
overall disease progression was 1/166 patient-years, or 0.60% per patient per year, and the
annual rate of progression to EAC was 1/166 patient-years, or 0.60% per patient per year.
Because we allowed cross-over to active treatment at 1 year, a comparator group to RFA is
no longer available. However, the annual progression rate in the SHAM cohort for this study
was 16.3%.
Three subjects had progression from LGD to HGD, one from HGD to EAC, and one from
LGD to EAC. For the 3 subjects that progressed from LGD to HGD, all were originally
randomized to RFA. Two remained in the study after detection of HGD and continued to
receive RFA. One achieved CE-D and CE-IM at 2 and 3 years while the other achieved CE-
D and CE-IM at 2 years, then withdrew consent. The third of these subjects had EMR of the
focal HGD and elected not to continue in the study. The 1 subject who progressed from
HGD to EAC has been previously described,7 and was originally randomized to RFA. In
this subject, focal intramucosal EAC was noted in a small nodule 3 months after primary
RFA, focal EMR was used to remove the nodule, and the subject then underwent subsequent
RFA. This subject was CE-D at 1 year, then CE-D and CE-IM at 2 and 3 years. The 1
subject who progressed from LGD to EAC was initially assigned to SHAM and completed
12 month follow-up with evidence of persistent multi-focal LGD. The subject crossed over
to active therapy, was treated with 3 sessions of RFA (one circumferential, and 2 focal),
demonstrated CE-IM at 12 months, but 6 months later was noted to have intramucosal EAC
located 1 cm proximal to the top of the gastric folds, which was treated curatively with
EMR. No disease progression-related morbidity or mortality has occurred in the study.
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To date, four serious adverse events have occurred in the 119 subjects (3.4%), designated by
the investigator as possibly or probably associated with the study procedure. The events
included: one upper GI hemorrhage in a subject that was receiving dual anti-platelet therapy
with aspirin and clopidogrel for heart disease, and whose bleeding was treated
endoscopically; one overnight hospitalization for new-onset chest pain 8 days after primary
RFA; and two overnight hospitalizations for chest discomfort and nausea immediately
following RFA. No perforations or procedure-related deaths occurred. Among the 119
subjects receiving any RFA, 9 developed esophageal stricturing (7.6% of subjects, 1.8% of
procedures), defined as endoscopically-identified narrowing with or without dysphagia. All
were successfully dilated to endoscopic resolution (mean 2.8 sessions).
Predictors of Response to Therapy
We assessed age, race, sex, BMI, initial degree of dysplasia, previous EMR, ASA/NSAID
use, hiatal hernia size, BE length and duration of BE diagnosis as predictors of incomplete
eradication of IM at the 2 year time-point. While subjects attaining CE-IM were, on average,
younger, more likely to be ASA/NSAID users, and more likely to have LGD than HGD,
none of these predictors was statistically significant in either bivariate analysis or logistical
regression (full models not shown).
Discussion
Endoscopic therapy of dysplastic Barrett’s esophagus with RFA has demonstrated a high
rate of CE-D and CE-IM, with an acceptable side effect profile.4, 7 The most important
remaining issues in this field are the durability of the treatment effect and the longer term
outcomes of therapy. Since durability of treatment effect is a determinant of the cost-
effectiveness of the procedure,10 and because subjects with recurrent BE after RFA are
presumably at continued risk for developing EAC, it is vital to know whether the
neosquamous epithelium present after RFA is durable.
Our study demonstrates that the majority of subjects treated with RFA demonstrate CE-D
and CE-IM at 2 and 3 year follow-up. In subjects who achieved CE-IM in this study and
then subsequently demonstrated recurrent disease, the amount of recurrent disease always
involved a minute proportion of the original BE surface area and the grade of recurrent
disease was at or below study entry grade in most patients. Half of recurrences (7/14)
occurred in subjects felt endoscopically to have either a normal or irregular Z line (without
tongues >5 mm in length). Whether some or all of these recurrences might have been
averted by mandating routine circumferential treatment of the Z line in the absence of
endoscopic evidence of BE is unknown.
Five of the 119 subjects (4.2%) who received RFA therapy as part of this trial did
demonstrate disease progression, representing an annual rate of progression of 1 case per 73
patient years (1.37%). While this annual rate is sizably lower than the 1-year progression
rate in the SHAM group (1 case per 6 patient years, 16.3%), it points out the need for
meticulous endoscopic monitoring of this high-risk population. Given the low number of
progressors in this trial, the progression rates we report must be viewed as imprecise.
Therefore, we are unable to comment on whether successful ablation (CE-IM after RFA)
might allow a lengthening of the currently recommended surveillance intervals for
dysplastic BE. However, if larger studies confirm the low rate of progression of treated
subjects demonstrated here, our current endoscopic surveillance protocols may be
unnecessarily aggressive for a successfully treated patient.
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The present study reports the longest duration of follow-up of subjects undergoing RFA for
dysplastic BE. Because subjects with dysplastic BE are at highest risk for progression to
cancer, such data are essential to understand the value of ablative therapy in the setting of
BE. Other strengths of our study include compulsive and complete accounting for all
subjects, expert histological analysis of biopsy samples by a central laboratory, a priori
protocols for endoscopic treatment, and standardized biopsy procedures with a large number
of samples taken. Limitations include the potential for underestimation of residual or
recurrent disease due to SSIM. Random biopsies may miss small areas of SSIM, or biopsies
may not sample deeply enough to detect residual columnar tissue. Another potential effect
of sampling error in this study is that some subjects designated as recurrent BE may have
instead had incomplete initial eradication, with false negative histology documenting disease
eradication. In such subjects, the apparent recurrent IM would rather truly be failure of the
initial therapy. Also, we reported 2 year outcomes based on the 106 of 119 patients that were
available for endoscopic biopsy, which could artificially elevate the rate of CE-D and CE-
IM if subjects withdrawing consent were more likely to have failed therapy. Therefore, we
have additionally reported the most conservative possible response rates considering these
13 patients lost to follow-up patients as failures in the 2 year outcomes, and response rates
remained acceptable [101/119 (85%) CE-D and 99/119 (83%) CE-IM]. Also, we allowed
subjects into the extension phase of the study only if CE-IM was attained at 2-year follow-
up or if a single session of salvage therapy with RFA after a 2-year failure achieved CE-IM.
While we felt it was not ethical to continue study participation in subjects who had not
responded to therapy by that time, this decision has the effect of artificially elevating our 3
year response rates as calculated by simple proportions, since 2-year failures are no longer in
the cohort. The Kaplan-Meier curve is, however, unaffected by this potential bias, since any
subject that did not qualify for the study extension would have reached the censoring event
for that analysis (and been considered a failure in the survival analysis). Another limitation
is that the study sites for this trial are experienced in the care of subjects with dysplastic BE,
following rigorous, a priori study protocols. Whether these results can be generalized to
community practice settings is unknown. Lastly, because we allowed crossover from the
sham arm to RFA, we no longer have a comparison group. While such a group would be
beneficial, the ethical issues involved in retaining a sham arm long-term given the risk for
disease progression were untenable.
These data add to a small, but growing, body of literature reporting the longterm outcomes
and durability of the reversion to squamous epithelium induced after RFA therapy. Fleischer
et al recently reported the five year results of their trial for subjects with non-dysplastic
BE.11 After primary circumferential RFA followed by touch-up focal RFA, this study
demonstrated CE-IM in 98% of evaluable patients at 2.5 year follow-up. In an extension of
their trial that did not allow for interval touch-up therapy after 2.5 years, 92% of evaluable
patients remained CE-IM at 5-year follow-up, suggesting that the reversion to neosquamous
epithelium after RFA is durable in non-dysplastic BE. In the 4 subjects who demonstrated
recurrent BE at 5 years, the magnitude of recurrence was minimal and a single additional
RFA resulted in subsequent CE-IM.
Pouw et al. reported 44 patients with BE containing HGD and or early cancer using EMR as
a diagnostic staging tool at baseline in most, followed by step-wise RFA. After a median of
21 months follow-up (IQR 10–27), CE-D and CE-IM were achieved in 43 of 44 patients
(98%) with no cases of recurrence after CE.12 In a retrospective study, Ganz and colleagues
reported on 92 subjects with BE and HGD undergoing RFA. At an average 12 months
follow-up, CE-D and CE-IM were achieved in 80% and 54%, respectively. Most patients in
this trial had a single circumferential ablation and no patient had focal ablation due to its
lack of availability.13 Lyday et al reported their experience with 429 subjects undergoing
RFA for BE in community practices. Of the 27 subjects in this group with dysplasia who
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were treated and followed for at least one year, all 27 were CE-D at a mean follow-up of 20
months, and 77% were CE-IM.4 In a multi-center prospective trial, Pouw et al. applied RFA
for patients with BE containing HGD and/or early cancer. At 22 months median follow-up
in 23 patients, CE-D and CE-IM were achieved at 95% and 88% of patients, respectively. A
single salvage EMR in 2 patients elevated the responses rates to 100% CE-D and 96% CE-
IM. Once CE-IM was achieved, no patients demonstrated recurrence.14 Sharma, et al.
treated patients with LGD (n=10) with RFA.15 At 2-year follow-up, CR-D and CE-IM were
100% and 90%, respectively. In a larger trial, Sharma et al. evaluated RFA in 63 patients
with dysplastic BE (39 LGD, 24 HGD). At a median follow-up of 2 years, CE-D and CE-IM
were achieved in 95% and 87% of LGD patients and 79% and 67% of HGD patients,
respectively. No patient demonstrated neoplastic progression, stricture, or buried glands.16
In a randomized controlled trial, Van Vilsteren, et al. compared RFA to EMR in patients
with up to 5 cm of BE containing HGD and or early cancer. At 24 months follow-up, similar
outcomes for CE were seen in each group: 100% CE-D and 92% CE-IM in the EMR group,
and 96% CE-D and 96% CE-IM in the RFA group. The stenosis rate in the EMR group was
significantly higher than that of the RFA group (88% vs. 14%, p<0.001), and there was one
perforation in the EMR group.17
In general, the above studies are in concordance with the present data, reporting high rates of
CE-D and CE-IM at 1 and 2 years. The remaining variability in outcomes data in these
studies may in part reflect the diverse patient populations in the studies, and the way that
treatment failure was defined, as well as the relatively recent availability of a focal ablation
device for treating the small area of residual BE after primary therapy or in cases of
recurrence. Predictors of response to therapy would allow better patient selection. While our
study did not demonstrate significant predictors at the 2 year time-point, it was not powered
to do so, and larger studies will be necessary to define these variables.
All of the subjects in the present study have been maintained on high-dose proton pump
inhibitor therapy with esomeprazole at 40 mg twice daily for the duration of the trial. While
this therapy is generally well-tolerated, the optimal medical regimen longterm for the subject
after successful ablative therapy is not known. While multiple observational studies suggest
that longterm maintenance therapy with high-dose proton pump inhibitor may expose the
subject to some increased risk of hip fracture,18, 19 pneumonia20, 21 or enteric infection,22, 23
a substantial proportion of subjects with BE will not normalize esophageal acid exposures
on once daily proton pump inhibitor therapy,24, 25 and the threat of recurrent neoplasia in
this high-risk group may warrant the higher doses of acid suppression. Further investigation
will be necessary to better understand optimal maintenance therapy of this population.
In conclusion, follow-up of the subjects from the AIM Dysplasia trial to an average of 3.05
years demonstrates that a high percentage of subjects with both low-grade and high-grade
dysplasia retain complete eradication of dysplasia and intestinal metaplasia after treatment.
Most subjects with recurrence of disease could again attain complete eradication of
intestinal metaplasia with further treatment. Progression of disease was rare in subjects who
underwent RFA treatment, and the rate of progression to EAC in this dysplastic cohort was
0.55%. There was no procedure- or cancer-related mortality. The main adverse side effect
was stricture occurrence, which occurred in 7.6% of subjects and was correctable with
dilation. Further systematic, prospective follow-up of this cohort will allow additional
assessment of long term outcomes of ablative therapy in dysplastic BE.
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Flow Diagram of Subjects progressing through the trial. Cross-over to active therapy is
represented by the arrows leading from the sham arm to active treatment.
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Kaplan-Meier analysis of the durability of complete eradication of dysplasia. All subjects in
this analysis achieved complete eradication of dysplasia at or after the 12 month endpoint
(n=110), and time 0 for this analysis is the first finding of complete eradication of dysplasia
at or after month 12. For purposes of this analysis, any recurrent dysplasia noted after
initially achieving CE-D was considered a failure, even if such recurrence was followed by
focal RFA and reestablishment of CE-D. HGD, High-grade dysplasia; LGD, Low-grade
dysplasia.
Shaheen et al. Page 14














Kaplan-Meier analysis of the durability of complete eradication of intestinal metaplasia. All
subjects in this analysis achieved complete eradication of dysplasia at or after the 12 month
endpoint (n=108), and time 0 for this analysis is the first finding of complete eradication of
intestinal metaplasia at or after month 12. For purposes of this analysis, any recurrent
intestinal metaplasia noted after initially achieving CE-IM was considered a failure, even if
such recurrence was followed by focal RFA and reestablishment of CE-IM. HGD, High-
grade dysplasia; LGD, Low-grade dysplasia; IM, intestinal metaplasia.
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Table 1
Baseline Characteristics of Treated Patients
LGD (n=58) HGD (n=61)
Age – mean ± SD 65.5 ± 9.1 66.4 ± 8.8
Male – no. (%) 47 (81) 55 (90)
BMI – mean ± SD 29.9± 5.7 28.6 ± 4.9
AA/W/Latino (%) 1/56/1 2/57/2
Multifocal dysplasia no. (%) 40 (69) 50 (82)
Length of BE cm – Mean ± SD 4.5 ± 2.3 5.2 ± 2.1
Hiatal Hernia – no. (%) 51 (88) 58 (95)
Previous EMR – no. (%) 5 (9) 5 (8)
Years with BE – mean ± SD 5.8 ± 4.6 5.1 ± 5.1
Abbreviations: BE, Barrett’s esophagus; HGD, high-grade dysplasia, LGD, low-grade dysplasia; BMI, body mass index; AA, African-American;
W, White; EMR, endoscopic mucosal resection.
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Table 2
Two- and Three-Year Outcomes of the AIM Dysplasia Trial.
CE-IM (Entire Cohort) n (%) CE-D (HGD Cohort) n (%) CE-D (LGD Cohort) n (%)
Year 2 99/106 (93) 50/54 (95) 51/52 (98)
Year 3 51/56 (91) 23/24 (96) 32/32 (100)
CE-IM and CE-D, allowing for interim focal touch-up RFA.
CE-IM, complete eradication of intestinal metaplasia; CE-D, complete eradication of dysplasia; HGD, high-grade dysplasia; LGD, low-grade
dysplasia
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